Editas Medicine (EDIT) Stock Price, Quote & News

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in No...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 401 9000

Website: www.editasmedicine.com

Address:

11 Hurley Street, Cambridge, United States

Winning_calls Dec. 8 at 4:34 AM

$EDIT pick me up @ $2.46

0 · Reply

StockBraker Dec. 7 at 1:09 PM

$EDIT https://www.nasdaq.com/articles/editas-medicine-edit-price-target-increased-2278-495

0 · Reply

3DBuilds Dec. 6 at 8:32 PM

$CRBU $EDIT $NTLA $PRME Caribou Biosciences CRISPR plants and animals patents 💯 Europe is now letting CRISPR plants and animals this is huge 💰 🌎

0 · Reply

3DBuilds Dec. 6 at 11:16 AM

$EDIT Great buy time 💯 💰 🌎

0 · Reply

Khaleesi_Rekindled Dec. 5 at 12:44 AM

$EDIT started a position.

1 · Reply

svertical1 Dec. 4 at 8:01 PM

$VRTX $CRSP $NTLA $EDIT Vertex is clear leader in: CF, SCD, TDT, Pain, Kidney, T1D Imagine then leading genetic engineering after CRSP buy🤞! Use their Billions to begin trials for the Top 100 genetic diseases. Keep 100%!of revenue! All Fast Tracked, with FDA onboard to Insure US Biotech remains preeminent over China and others.

1 · Reply

Whoami1989 Dec. 4 at 6:11 PM

$EDIT time for drug addicted day traders to cash out money for beers and prostitution.

0 · Reply

Whoami1989 Dec. 4 at 4:28 PM

$EDIT you mf loser better hits $3 today

0 · Reply

harryvanluik Dec. 4 at 3:27 PM

$EDIT I don't know if there is any meat in the rumours of a buy-out of CRSP Technologies by Vertex... that would light te fire on this hard-beaten sector. Furthermore: I wouldn't be surprised if Edit will enjoy a major jump since we are waiting for the announcement of the new target in our research which can be revealed any day now. On top I still expect news from the patent-litigation and last but not least: the NTLA-issue has had an absolutely ridiculous impact on the Edit-stockprice because traders have taken advantage of the situation to talk this stock down: now they will have to talk it up to make big profits. Conclusion: I am expecting fireworks here in the next few days and weeks. GLTY

1 · Reply

0x126 Dec. 3 at 10:23 PM

$EDIT sector move but I'll take it any day. NTLA FDA letter may send us ballistic again.

0 · Reply

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Nov 3, 2025, 9:00 AM EST - 4 weeks ago

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Oct 14, 2025, 6:18 PM EDT - 7 weeks ago

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Oct 9, 2025, 11:01 AM EDT - 2 months ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Oct 6, 2025, 9:00 AM EDT - 2 months ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Sep 2, 2025, 11:14 AM EDT - 3 months ago

Editas Medicine, Inc. - Special Call

Sep 2, 2025, 7:00 AM EDT - 3 months ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Aug 28, 2025, 4:01 PM EDT - 3 months ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Aug 27, 2025, 9:00 AM EDT - 3 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Aug 15, 2025, 7:50 AM EDT - 4 months ago

Why Editas Medicine Stock Was Skyrocketing This Week

Aug 12, 2025, 4:01 PM EDT - 4 months ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Jun 28, 2025, 5:04 AM EDT - 5 months ago

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

Jun 27, 2025, 8:15 AM EDT - 5 months ago

2 Beaten-Down Stocks to Avoid

SRPT

Jun 17, 2025, 10:07 AM EDT - 6 months ago

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

Jun 12, 2025, 2:01 AM EDT - 6 months ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

May 25, 2025, 6:00 AM EDT - 7 months ago

1 Stock Down 97% That Could Double, According to Wall Street

May 20, 2025, 5:47 AM EDT - 7 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT NTLA VANI VERV

May 15, 2025, 7:30 PM EDT - 7 months ago

Editas Medicine: A Cautionary Tale for Investors

May 14, 2025, 2:17 PM EDT - 7 months ago

Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 9:31 AM EDT - 7 months ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 7:01 AM EDT - 7 months ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 7:01 AM EDT - 7 months ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 12, 2025, 4:30 PM EDT - 7 months ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:01 PM EDT - 7 months ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 5, 2025, 4:01 PM EDT - 7 months ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Apr 28, 2025, 4:31 PM EDT - 7 months ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 9 months ago

Editas Medicine Announces Chief Financial Officer Transition

Mar 11, 2025, 4:07 PM EDT - 9 months ago

Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 10, 2025, 12:19 PM EDT - 9 months ago

Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)

Mar 5, 2025, 4:05 PM EST - 9 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Mar 3, 2025, 5:01 PM EST - 9 months ago

Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript

Feb 24, 2025, 9:00 AM EST - 10 months ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Jan 17, 2025, 12:20 PM EST - 11 months ago

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

NTLA

Jan 15, 2025, 4:35 PM EST - 11 months ago

Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 13, 2025, 9:00 AM EST - 11 months ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 6, 2025, 9:00 AM EST - 11 months ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 6:44 AM EST - 1 year ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Dec 12, 2024, 6:03 PM EST - 1 year ago

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 4:00 PM EST - 1 year ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 9, 2024, 12:00 PM EST - 1 year ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 3, 2024, 10:52 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Nov 25, 2024, 12:59 PM EST - 1 year ago

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Nov 19, 2024, 7:53 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Oct 22, 2024, 11:45 AM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript

Oct 21, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 18, 2024, 4:01 PM EDT - 1 year ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 7, 2024, 3:33 PM EDT - 1 year ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 6, 2024, 2:00 PM EDT - 1 year ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EXAS NTLA

Oct 3, 2024, 6:00 PM EDT - 1 year ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Winning_calls Dec. 8 at 4:34 AM

$EDIT pick me up @ $2.46

0 · Reply

StockBraker Dec. 7 at 1:09 PM

$EDIT https://www.nasdaq.com/articles/editas-medicine-edit-price-target-increased-2278-495

0 · Reply

3DBuilds Dec. 6 at 8:32 PM

$CRBU $EDIT $NTLA $PRME Caribou Biosciences CRISPR plants and animals patents 💯 Europe is now letting CRISPR plants and animals this is huge 💰 🌎

0 · Reply

3DBuilds Dec. 6 at 11:16 AM

$EDIT Great buy time 💯 💰 🌎

0 · Reply

Khaleesi_Rekindled Dec. 5 at 12:44 AM

$EDIT started a position.

1 · Reply

svertical1 Dec. 4 at 8:01 PM

1 · Reply

Whoami1989 Dec. 4 at 6:11 PM

$EDIT time for drug addicted day traders to cash out money for beers and prostitution.

0 · Reply

Whoami1989 Dec. 4 at 4:28 PM

$EDIT you mf loser better hits $3 today

0 · Reply

harryvanluik Dec. 4 at 3:27 PM

1 · Reply

0x126 Dec. 3 at 10:23 PM

$EDIT sector move but I'll take it any day. NTLA FDA letter may send us ballistic again.

0 · Reply

Whoami1989 Dec. 3 at 8:31 PM

$EDIT can this mf fpos go over 2.40?

0 · Reply

0x126 Dec. 3 at 7:07 PM

$EDIT https://youtu.be/nVQo76iEoms lfg

0 · Reply

Whoami1989 Dec. 3 at 6:08 PM

$EDIT Any charter predicts bottom? idiotic day traders are about to cash out. still fpos

0 · Reply

HarryScrotmmm Dec. 3 at 3:19 PM

$EDIT 2.12 yesterday now today let's see if that holds.

0 · Reply

NinjaXLightning Dec. 3 at 12:51 AM

$EDIT Watching to add soon. They announce new target soon and have very effectively extended cash runway until they can prove some clinical results.

0 · Reply

Whoami1989 Dec. 2 at 9:04 PM

$EDIT the whole loser management team need to be cleansed very soon

0 · Reply

ppstream Dec. 2 at 9:02 PM

$EDIT somebody really tries really hard to bring that down…I wonder who‘s behind this…

1 · Reply

Whoami1989 Dec. 2 at 9:01 PM

$EDIT this complete loser is done

0 · Reply

Whoami1989 Dec. 2 at 8:49 PM

$EDIT this fpos never disappointed me

0 · Reply

harryvanluik Dec. 2 at 6:18 PM

$EDIT Is management asleep? Let them show how loyal they are and how much they believe in the future of EDIT: BUY SHARES!!!! All other shareholders: raise your voices and get off your a&2@s: promote this stock for your own benefit!

0 · Reply

HarryScrotmmm Dec. 2 at 5:02 PM

$EDIT no volume on this decline.

1 · Reply

Whoami1989 Dec. 2 at 4:57 PM

$EDIT again market is up, and this MF fpos is dipping. something is seriously wrong with this MF

0 · Reply

Market Cap	236.24M
Revenue (ttm)	32.31M
Net Income (ttm)	-237.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-733.80%
Debt to Equity Ratio	0.00

Volume	1,354,700
Avg Vol	2,480,090
Day's Range	N/A - N/A
Shares Out	97.62M
Stochastic %K	72%
Beta	2.44
Analysts	Sell
Price Target	$4.55